Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $107.24, for a total value of $2,144,800.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $82,336,727.20. The trade was a 2.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00.
• On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00.
• On Wednesday, July 8th, Helen Torley sold 1,923 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $79.77, for a total value of $153,397.71.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded up $0.20 during midday trading on Friday, hitting $107.20. The stock had a trading volume of 861,533 shares, compared to its average volume of 1,560,954. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $111.15. The company has a market capitalization of $12.17 billion, a PE ratio of 32.00, a P/E/G ratio of 0.41 and a beta of 0.88. The firm’s fifty day moving average is $93.73 and its two-hundred day moving average is $76.97. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current year.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors have recently bought and sold shares of the stock. MidFirst Bank bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at about $27,000. Larson Financial Group LLC boosted its stake in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Halozyme Therapeutics during the second quarter valued at approximately $28,000. Measured Wealth Private Client Group LLC grew its holdings in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at approximately $30,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HALO has been the topic of a number of analyst reports. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $83.00 to $110.00 in a research note on Friday, August 7th. Citizens Jmp increased their price target on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. HC Wainwright restated a “buy” rating and issued a $115.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, September 2nd. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.